Our mission is to become a worldwide reference for education in the field for all professionals involved in the process to disseminate knowledge & skills of Acute Cardiovascular Care.
Our mission is to promote excellence in clinical diagnosis, research, technical development, and education in cardiovascular imaging in Europe.
Our mission is to promote excellence in research, practice, education and policy in cardiovascular health, primary and secondary prevention.
Our mission is to reduce the burden of cardiovascular disease in Europe through percutaneous cardiovascular interventions.
Our mission is to improve the quality of life of the population by reducing the impact of cardiac rhythm disturbances and reduce sudden cardiac death.
Our mission is to improve quality of life and longevity, through better prevention, diagnosis and treatment of heart failure, including the establishment of networks for its management, education and research.
The ESC Working Groups' goal is to stimulate and disseminate scientific knowledge in different fields of cardiology.
The ESC Councils' goal is to share knowledge among medical professionals practising in specific cardiology domains.
OUR MISSION: TO REDUCE THE BURDEN OF CARDIOVASCULAR DISEASE
Curriculum Vitae:October 2001 - On going: PhD student in vascular biology, Medical University of ViennaAugust 2008 - ongoing: Research fellow at the Department of Internal Medicine II - Division of Cardiology; main field of research: ischemia-reperfusion injury, SIRS, inflammatory processes in atherosclerosis2005 - 2011: Study of medicine, Medical University of Vienna2004 - ongoing: paramedic & lecturer at St. John's Ambulance Vienna
Inhibition of pro-inflammatory effects in human cardiac myocytes and endothelial cells by levosimendan
In clinical trials it was shown that levosimendan is particularly effective in patients suffering from acute decompensated heart failure due to myocardial infarction. We hypothesized that levosimendan might exhibit anti-inflammatory effects on human cardiac myocytes and endothelial cells and by that dampen the myocardial reperfusion injury.
We hypothesized that levosimendan exhibits its beneficial effects during myocardial infarction and reperfusion injury by dampening the inflammatory response. Therefore, we induced inflammation in human cardiac myocytes and endothelial cells by adding inflammatory agents (TNF-α and IL-1b) and co-treated some of the cells with different concentrations of levosimendan (0.1 - 10 µM). Co-treatment with levosimendan lead to a marked reduction of IL-6 and IL-8 production by myocytes, down-regulation of adhesion molecules and attenuation of granulocyte adherence in endothelial cells.
This award by the acute cardiac care association lead to further recognition of my work by peers and seniors at my institution. This may be of help for finding a residency position for cardiology at a competitive department. On a personal level, it encouraged me to keep my enthusiasm for the basic and clinical research I am currently conducting.
For me, participation in this young ESC association may enhance international exchange with both seniors in this exciting field and peers that stand at the beginning of their career in cardiology and acute cardiac care like me. Exchange may include scientific exchange in the form of abstracts, poster or oral presentations at the annual conference, publication in the journal and the possibility of clinical exchange. Guidelines and position papers on hot or controversial topics in acute cardiac care may help and guide young cardiologists in their daily clinical practice.
© 2017 European Society of Cardiology. All rights reserved